Almado Inc

Almado Inc maintains a levered capital structure with total liabilities of ¥28.5 billion and equity of ¥1.87 billion, resulting in a debt-to-equity ratio of 1.12. The company holds ¥1.57 billion in cash and equivalents, but its operating cash flow is negative at ¥189 million, and free cash flow is also negative at ¥35.7 million, indicating liquidity constraints. The price-to-book ratio of 3.51 suggests the market values the company at a premium to its book value, while the price-to-tangible-book ratio is identical, implying intangible assets are not material to the valuation. Profitability metrics show a gross margin of 69.9% (¥5.92 billion gross profit on ¥8.48 billion revenue) and an operating margin of 11.2% (¥946 million operating income). Return on equity (ROE) of 34.7% and return on assets (ROA) of 13.8% outperform the typical Personal Products industry benchmarks of 15-20% ROE and 8-12% ROA, indicating strong asset utilization and profitability. The company's revenue is concentrated in its Eggshell Membrane Healthcare segment, with no disclosed geographic diversification. All production is outsourced, and sales are distributed through TV shopping (QVC), direct e-commerce, and OEM channels. The CELLULA and Ode series are the primary revenue drivers, but the lack of geographic or product diversification increases exposure to market-specific risks. Revenue growth has been modest, with a current fiscal year outlook showing a 2.1% increase to ¥8.65 billion and a next fiscal year projection of 4.3% growth to ¥8.99 billion. This aligns with the company's strategy of expanding direct-to-consumer sales and leveraging TV shopping channels, but the reliance on a narrow product portfolio may limit long-term scalability. The risk assessment highlights liquidity as a medium concern, with negative free cash flow and a current ratio of 1.59. The company's debt load is partially offset by cash reserves, but the net cash position is negative after subtracting total debt. Dilution risk is assessed as low, with no near-term pressure from share issuance or convertible debt. However, the company's reliance on outsourced production and a single product line increases operational and supply chain risks. Recent events include the 2023 annual report filing, which disclosed continued expansion of the CELLULA series and QVC channel partnerships. No material regulatory or litigation risks were reported, but the company's exposure to consumer trends and raw material costs remains a key vulnerability.